Published in J Clin Oncol on September 01, 1990
Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 study. Int J Radiat Oncol Biol Phys (2011) 1.02
Delayed primary excision with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee. Int J Cancer (2014) 0.88
The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet (1995) 5.83
Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med (1999) 4.22
Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy. J Clin Oncol (1996) 2.59
Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci U S A (1995) 2.56
The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet (1997) 2.28
A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting. Proc Natl Acad Sci U S A (1989) 2.02
Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol (1993) 2.01
Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol (2000) 1.98
Childhood non-Hodgkin's lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2). N Engl J Med (1983) 1.82
Determinants of the use of complementary therapies by patients with cancer. J Clin Oncol (2001) 1.69
Non-Hodgkin's lymphoma in children. A comparative study of two modalities of therapy. Cancer (1976) 1.64
Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer. Am J Obstet Gynecol (1996) 1.59
Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. Am J Pathol (2000) 1.52
A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers. Br J Cancer (2004) 1.41
Inhibition of tumor metastasis by heparanase inhibiting species of heparin. Invasion Metastasis (1995) 1.34
Prevalence and functional consequence of PHOX2B mutations in neuroblastoma. Oncogene (2007) 1.30
CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers. Br J Cancer (2001) 1.27
Transfusion-associated acute Chagas disease acquired in the United States. Ann Intern Med (1989) 1.25
The effect of age at diagnosis on outcome in rhabdomyosarcoma. Cancer (1994) 1.23
The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer. Am J Hum Genet (1999) 1.19
Expression level, allelic origin, and mutation analysis of the p73 gene in neuroblastoma tumors and cell lines. Cell Growth Differ (1998) 1.17
Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril (1996) 1.16
Multimarker RT-PCR assay for the detection of minimal residual disease in sentinel lymph nodes of breast cancer patients. Br J Cancer (2006) 1.12
Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood (1996) 1.08
Tumor suppressor p53 regulates heparanase gene expression. Oncogene (2006) 1.07
Preimplantation genetic diagnosis for BRCA1/2--a novel clinical experience. Prenat Diagn (2009) 1.05
Liposarcoma in patients younger than or equal to 22 years of age. Cancer (1993) 1.05
Molecular properties and involvement of heparanase in cancer progression and mammary gland morphogenesis. J Mammary Gland Biol Neoplasia (2001) 1.04
Prognostic significance of regional lymph node involvement in childhood extremity rhabdomyosarcoma. Med Pediatr Oncol (1990) 1.04
Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma. J Skin Cancer (2013) 1.02
Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. Br J Cancer (1991) 1.02
Primary colorectal sarcoma. A retrospective review and prognostic factor study of 50 consecutive patients. Arch Surg (1990) 1.00
Outcome of patients with a history of bilateral retinoblastoma treated for a second malignancy: the Memorial Sloan-Kettering experience. Med Pediatr Oncol (1998) 1.00
A prospective, randomized evaluation of the effect of silver impregnated subcutaneous cuffs for preventing tunneled chronic venous access catheter infections in cancer patients. Ann Surg (1993) 0.99
Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study. Eur J Cancer Clin Oncol (1989) 0.98
N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Med Pediatr Oncol (2001) 0.98
Bowel perforation during initial treatment for childhood non-Hodgkin's lymphoma. Cancer (1985) 0.96
Genitourinary rhabdomyosarcoma in children. J Pediatr Surg (1978) 0.96
Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation. Clin Oncol (R Coll Radiol) (2007) 0.96
Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival. Br J Cancer (2007) 0.95
Influenza immunization of children with neoplastic diseases. Cancer (1980) 0.95
Local control with multimodality therapy for stage 4 neuroblastoma. Int J Radiat Oncol Biol Phys (2000) 0.95
A deletion/insertion mutation in the BRCA2 gene in a breast cancer family: a possible role of the Alu-polyA tail in the evolution of the deletion. Genes Chromosomes Cancer (2001) 0.95
High-dose methotrexate with citrovorum factor rescue for the treatment of central nervous system tumors in children. Cancer Treat Rep (1977) 0.94
The role of surgery in abdominal non-Hodgkin's lymphoma: experience from the Childrens Cancer Study Group. J Pediatr Surg (1992) 0.94
Pulmonary function in children treated for rhabdomyosarcoma. Med Pediatr Oncol (1996) 0.92
Haplotype analysis of BRCA2 8765delAG mutation carriers in French Canadian and Yemenite Jewish hereditary breast cancer families. Hum Hered (2001) 0.91
Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma. Br J Cancer (2004) 0.91
Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol (1994) 0.90
Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer. Br J Cancer (2002) 0.90
Double heterozygotes for the Ashkenazi founder mutations in BRCA1 and BRCA2 genes. Am J Hum Genet (1998) 0.90
EZH2 promotes a bi-lineage identity in basal-like breast cancer cells. Oncogene (2013) 0.90
Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in israel. Gynecol Oncol (2003) 0.90
Phosphorylation of a K+ channel alpha subunit modulates the inactivation conferred by a beta subunit. Involvement of cytoskeleton. J Biol Chem (1996) 0.89
The 8765delAG mutation in BRCA2 is common among Jews of Yemenite extraction. Am J Hum Genet (1998) 0.88
Multidisciplinary treatment of embryonal rhabdomyosarcoma in children. Cancer (1975) 0.88
Factors predictive of mortality in pediatric extremity rhabdomyosarcoma. J Pediatr Surg (1990) 0.87
Endocrine sequelae of antineoplastic therapy in childhood head and neck malignancies. J Clin Endocrinol Metab (1980) 0.87
Glutathione-S-transferase M1, T1 and P1 polymorphisms, and breast cancer risk, in BRCA1/2 mutation carriers. Br J Cancer (2008) 0.87
Emerging role of laparoscopy in the diagnosis of lymphoma. J Clin Oncol (1998) 0.87
Sulfate moieties in the subendothelial extracellular matrix are involved in basic fibroblast growth factor sequestration, dimerization, and stimulation of cell proliferation. J Biol Chem (1996) 0.86
Chest wall rhabdomyosarcoma. Cancer (1997) 0.86
Transmission of response to trauma? Second-generation Holocaust survivors' reaction to cancer. Am J Psychiatry (2000) 0.86
Laminarin sulfate mimics the effects of heparin on smooth muscle cell proliferation and basic fibroblast growth factor-receptor binding and mitogenic activity. J Cell Physiol (1995) 0.85
Psychological intervention in cancer patients: a randomized study. Gen Hosp Psychiatry (2001) 0.85
Kinetics of primary tumor regression with chemotherapy: implications for the timing of surgery. Ann Surg Oncol (1996) 0.85
Myeloablative combination chemotherapy without total body irradiation for neuroblastoma. J Clin Oncol (1991) 0.85
Cisplatin-induced non-convulsive encephalopathy. Anticancer Drugs (1998) 0.85
High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseous Ewing's sarcoma, and undifferentiated sarcoma. J Clin Oncol (1998) 0.85
Regulation of RCK1 currents with a cAMP analog via enhanced protein synthesis and direct channel phosphorylation. J Biol Chem (1995) 0.84
Hypothalamic-pituitary-adrenal function following cranial irradiation. Horm Res (1997) 0.84
Interleukin-6 secretion in mice is associated with reduced glucose-6-phosphatase and liver glycogen levels. Am J Physiol (1997) 0.83
Redefined role of radiation in combined treatment of Ewing's sarcoma. Pediatr Hematol Oncol (1986) 0.83
Pediatric rhabdomyosarcoma of the head and neck. Am J Surg (1997) 0.83
Treatment of genitourinary rhabdomyosarcoma in children. J Urol (1984) 0.83
Primary nasal-paranasal oropharyngeal lymphoma in the pediatric age group. Cancer (1990) 0.83
Effect of low-dose radiation therapy when combined with surgical resection for Ewing sarcoma. Med Pediatr Oncol (1999) 0.83
The Effect of Genetic Counseling on Knowledge and Perceptions Regarding Risks for Breast Cancer. J Genet Couns (1998) 0.82
Holocaust cancer patients: a comparative study. Psychiatry (1993) 0.82
Prognostic factors in bladder and bladder-prostate rhabdomyosarcoma. J Pediatr Surg (1990) 0.82
Acute and late effects on normal tissues following combined chemo- and radiotherapy for childhood rhabdomyosarcoma and Ewing's sarcoma. Cancer (1976) 0.82
Inactivation of a voltage-dependent K+ channel by beta subunit. Modulation by a phosphorylation-dependent interaction between the distal C terminus of alpha subunit and cytoskeleton. J Biol Chem (1997) 0.82
Production and purification of melanoma gp100 antigen and polyclonal antibodies. Protein Expr Purif (2004) 0.82
Tumor necrosis factor inhibits the transcriptional rate of glucose-6-phosphatase in vivo and in vitro. Metabolism (1997) 0.82
Hodgkin's disease in children. Results of management between 1970-1981. Cancer (1983) 0.81
Mediastinal lymph node metastases from gastrointestinal carcinoma. Cancer (1987) 0.81
Intussusception due to pyogenic granuloma of ileum. N Y State J Med (1967) 0.81
Use of tranquilizers and sleeping pills among cancer patients is associated with a poorer quality of life. Qual Life Res (2004) 0.81
Correlation of MYCN amplification, Trk-A and CD44 expression with clinical stage in 250 patients with neuroblastoma. Eur J Cancer (1997) 0.80
Changes in cytokine production of breast cancer patients treated with interferons. Cytokine (1998) 0.80
Immediate and long-term posttherapy neuropsychologic performance in children with acute lymphoblastic leukemia treated without central nervous system radiation. J Pediatr (1982) 0.80
Informal caregiving to older cancer patients: preliminary research outcomes and implications. Ann Oncol (2013) 0.80
Can fetal and newborn allografts survive in an immunocompetent host? J Pediatr Surg (1986) 0.79
p53 controls hPar1 function and expression. Oncogene (2008) 0.79
Primary hepatic or hepatosplenic non-Hodgkin's lymphoma in children. Cancer (1983) 0.79
Targeting pulmonary metastases of renal cell carcinoma by inhalation of interleukin-2. Ann Oncol (2004) 0.79